Not Jazzed About Xyrem REMS, Irish Company Begins Dispute Resolution
This article was originally published in The Pink Sheet Daily
Executive Summary
Jazz will begin dispute resolution with FDA regarding the risk evaluation and mitigation strategy for its best-selling wakefulness drug.